Literature DB >> 21119562

Identification of new carbohydrate and membrane protein antigens in cardiac xenotransplantation.

Guerard W Byrne1, Paul G Stalboerger, Zeji Du, Tessa R Davis, Christopher G A McGregor.   

Abstract

BACKGROUND: α1,3-Galactosyltransferase gene knockout (GTKO) pigs reduced the significance of antibody to galactose alpha 1,3-galactose (Gal) antigens but did not eliminate delayed xenograft rejection (DXR). We hypothesize that DXR of GTKO organs results from an antibody response to a limited number of non-Gal endothelial cell (EC) membrane antigens. In this study, we screened a retrovirus expression library to identify EC membrane antigens detected after cardiac xenotransplantation.
METHODS: Expression libraries were made from GT:CD46 and GTKO porcine aortic ECs. Viral stocks were used to infect human embryonic kidney cells (HEK) that were selected by flow cytometry for IgG binding from sensitized cardiac heterotopic xenograft recipients. After three to seven rounds of selection, individual clones were assessed for non-Gal IgG binding. The porcine complementary DNA was recovered by polymerase chain reaction amplification, sequenced, and identified by homology comparisons.
RESULTS: A total of 199 and 317 clones were analyzed from GT:CD46 and GTKO porcine aortic EC complementary DNA libraries, respectively. Sequence analysis identified porcine CD9, CD46, CD59, and the EC protein C receptor. We also identified porcine annexin A2 and a glycosyltransferase with homology to the human β1,4 N-acetylgalactosaminyl transferase 2 gene.
CONCLUSION: The identified proteins include key EC functions and suggest that non-Gal antibody responses may compromise EC functions and thereby contribute to DXR. Recovery of the porcine β1,4 N-acetylgalactosaminyl transferase 2 suggests that an antibody response to a SD-like carbohydrate may represent a new carbohydrate moiety involved in xenotransplantation. The identification of these porcine gene products may lead to further donor modification to enhance resistance to DXR and further reduce the level of xenograft antigenicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21119562     DOI: 10.1097/TP.0b013e318203c27d

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  45 in total

1.  Evaluation of human and non-human primate antibody binding to pig cells lacking GGTA1/CMAH/β4GalNT2 genes.

Authors:  Jose L Estrada; Greg Martens; Ping Li; Andrew Adams; Kenneth A Newell; Mandy L Ford; James R Butler; Richard Sidner; Matt Tector; Joseph Tector
Journal:  Xenotransplantation       Date:  2015-03-01       Impact factor: 3.907

2.  Is there a correlation between anti-pig antibody levels in humans and geographic location during childhood?

Authors:  Goutham Kumar; Vikas Satyananda; Jason Fang; Hao Zhou; Minoru Fujita; Burcin Ekser; Cassandra Long; Eefje Dons; Qing Sun; David Ayares; Hidetaka Hara; David K C Cooper
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

3.  Silencing porcine genes significantly reduces human-anti-pig cytotoxicity profiles: an alternative to direct complement regulation.

Authors:  James R Butler; Gregory R Martens; Jose L Estrada; Luz M Reyes; Joseph M Ladowski; Cesare Galli; Andrea Perota; Conor M Cunningham; Matthew Tector; A Joseph Tector
Journal:  Transgenic Res       Date:  2016-04-21       Impact factor: 2.788

4.  Pre-transplant antibody screening and anti-CD154 costimulation blockade promote long-term xenograft survival in a pig-to-primate kidney transplant model.

Authors:  Laura Higginbotham; Dave Mathews; Cynthia A Breeden; Mingqing Song; Alton Brad Farris; Christian P Larsen; Mandy L Ford; Andrew J Lutz; Matthew Tector; Kenneth A Newell; A Joseph Tector; Andrew B Adams
Journal:  Xenotransplantation       Date:  2015-04-03       Impact factor: 3.907

Review 5.  In Search of the Ideal Valve: Optimizing Genetic Modifications to Prevent Bioprosthetic Degeneration.

Authors:  Benjamin Smood; Hidetaka Hara; David C Cleveland; David K C Cooper
Journal:  Ann Thorac Surg       Date:  2019-03-02       Impact factor: 4.330

Review 6.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

7.  Reduced binding of human antibodies to cells from GGTA1/CMAH KO pigs.

Authors:  C Burlak; L L Paris; A J Lutz; R A Sidner; J Estrada; P Li; M Tector; A J Tector
Journal:  Am J Transplant       Date:  2014-06-06       Impact factor: 8.086

8.  Human CD55 expression blocks hyperacute rejection and restricts complement activation in Gal knockout cardiac xenografts.

Authors:  Christopher G A McGregor; Davide Ricci; Naoto Miyagi; Paul G Stalboerger; Zeji Du; Elise A Oehler; Henry D Tazelaar; Guerard W Byrne
Journal:  Transplantation       Date:  2012-04-15       Impact factor: 4.939

Review 9.  Immunobiology of liver xenotransplantation.

Authors:  Burcin Ekser; Christopher Burlak; Joshua P Waldman; Andrew J Lutz; Leela L Paris; Massimiliano Veroux; Simon C Robson; Michael A Rees; David Ayares; Bruno Gridelli; A Joseph Tector; David Kc Cooper
Journal:  Expert Rev Clin Immunol       Date:  2012-09       Impact factor: 4.473

10.  Development of a consensus protocol to quantify primate anti-non-Gal xenoreactive antibodies using pig aortic endothelial cells.

Authors:  Agnes M Azimzadeh; Guerard W Byrne; Mohamed Ezzelarab; Emily Welty; Gheorghe Braileanu; Xiangfei Cheng; Simon C Robson; Christopher G A McGregor; David K C Cooper; Richard N Pierson
Journal:  Xenotransplantation       Date:  2014-09-01       Impact factor: 3.907

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.